Zelira Therapeutics (AU:ZLD) has released an update.
Zelira Therapeutics has made significant strides in its HOPE® program, receiving positive feedback from the FDA to advance towards IND submission and clinical trials. The company is also on track to transform Zenivol® into a capsule formulation by early 2025, enhancing its product offerings in cannabinoid medicines. These developments position Zelira as a key player in the pharmaceutical market, particularly in treating irritability in Phelan McDermid Syndrome comorbid with Autism Spectrum Disorder.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
